These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36703716)

  • 1. Factors in rural community buprenorphine dispensing.
    Major EG; Wilson CG; Carpenter DM; Harless JC; Marley GT; Ostrach B
    Explor Res Clin Soc Pharm; 2023 Mar; 9():100204. PubMed ID: 36703716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ensuring buprenorphine access in rural community pharmacies to prevent overdoses.
    Ostrach B; Potter R; Wilson CG; Carpenter D
    J Am Pharm Assoc (2003); 2022; 62(2):588-597.e2. PubMed ID: 34674965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. North Carolina community pharmacists' buprenorphine dispensing practices and attitudes.
    Carpenter D; Lambert KV; Harless JC; Wilson CG; Davis SA; Zule WA; Ostrach B
    J Am Pharm Assoc (2003); 2022; 62(5):1606-1614. PubMed ID: 35643625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Community Pharmacists' Knowledge and Perceptions of Buprenorphine for Patients with Opioid Use Disorder.
    Tutag Lehr V; Nolan C
    J Addict Med; 2023 Jul-Aug 01; 17(4):e224-e231. PubMed ID: 37579094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perceptions, policies, and practices related to dispensing buprenorphine for opioid use disorder: A national survey of community-based pharmacists.
    Hill LG; Light AE; Green TC; Burns AL; Sanaty Zadeh P; Freeman PR
    J Am Pharm Assoc (2003); 2023; 63(1):252-260.e6. PubMed ID: 36202711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Buprenorphine dispensing in an epicenter of the U.S. opioid epidemic: A case study of the rural risk environment in Appalachian Kentucky.
    Cooper HL; Cloud DH; Freeman PR; Fadanelli M; Green T; Van Meter C; Beane S; Ibragimov U; Young AM
    Int J Drug Policy; 2020 Nov; 85():102701. PubMed ID: 32223985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rural community pharmacist willingness to dispense Suboxone® - A secret shopper investigation in South-Central Appalachia.
    Trull G; Major E; Harless C; Zule W; Ostrach B; Carpenter D
    Explor Res Clin Soc Pharm; 2021 Dec; 4():100082. PubMed ID: 35479845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Brief Online Training to Address Pharmacists' Willingness to Dispense Buprenorphine.
    Carpenter D; Mashburn P; Viracola C; Marley G; Ostrach B
    J Addict Med; 2024 Jan-Feb 01; 18(1):68-70. PubMed ID: 37948129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationships Between Stigma, Risk Tolerance, and Buprenorphine Dispensing Intentions Among Community-Based Pharmacists: Results From a National Sample.
    Light AE; Green TC; Freeman PR; Zadeh PS; Burns AL; Hill LG
    Subst Use Addctn J; 2024 Apr; 45(2):211-221. PubMed ID: 38258805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addressing buprenorphine bottlenecks in the context of MAT Act implementation: A shared responsibility.
    Ostrach B; Hill L; Carpenter D; Pollini R
    J Am Pharm Assoc (2003); 2023; 63(4):1044-1048. PubMed ID: 37149144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identifying barriers to dispensing naloxone: A survey of community pharmacists in North Carolina.
    Rudolph SE; Branham AR; Rhodes LA; Hayes HH; Moose JS; Marciniak MW
    J Am Pharm Assoc (2003); 2018; 58(4S):S55-S58.e3. PubMed ID: 30006187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DEA Disconnect Leads to Buprenorphine Bottlenecks.
    Ostrach B; Carpenter D; Cote LP
    J Addict Med; 2021 Jul-Aug 01; 15(4):272-275. PubMed ID: 33181577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Communication Experiences of DATA-Waivered Physicians with Community Pharmacists: A Qualitative Study.
    Ventricelli DJ; Mathis SM; Foster KN; Pack RP; Tudiver F; Hagemeier NE
    Subst Use Misuse; 2020; 55(3):349-357. PubMed ID: 31591924
    [No Abstract]   [Full Text] [Related]  

  • 14. A content review of buprenorphine training programs for pharmacists.
    Davis SA; Dryer R; Zule W; Ostrach B; Carpenter DM
    Explor Res Clin Soc Pharm; 2022 Jun; 6():100154. PubMed ID: 35813287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding the role of community pharmacies in current medication for opioid use disorder care practices.
    Comanici KH; Nichols MA; Scott C; Conklin M; Ott CA; Arnett S; Karwa R
    J Am Pharm Assoc (2003); 2023; 63(1):261-268.e2. PubMed ID: 36209034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacists' nonprescription syringe dispensing perceptions and behaviors: A three-state descriptive analysis.
    Hagemeier NE; Dowling-McClay K; Baladezaei M; Curtis SJ; Spence M
    Drug Alcohol Depend; 2021 Apr; 221():108597. PubMed ID: 33631542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Community pharmacy-based injectable naltrexone service delivery models and best practices.
    Ford JH; Gilson AM; Bryan G; Augustine C; Gassman M; Mott DA
    Res Social Adm Pharm; 2021 Jul; 17(7):1332-1341. PubMed ID: 33268242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacists' and technicians' perceptions and attitudes toward dispensing buprenorphine/ naloxone to patients with opioid dependence.
    Raisch DW; Fudala PJ; Saxon AJ; Walsh R; Casadonte P; Ling W; Johnson BA; Malkerneker U; Ordorica P; Williford WO; Sather MR
    J Am Pharm Assoc (2003); 2005; 45(1):23-32. PubMed ID: 15730114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Barriers and facilitators to dispensing of intranasal naloxone by pharmacists.
    Bakhireva LN; Bautista A; Cano S; Shrestha S; Bachyrycz AM; Cruz TH
    Subst Abus; 2018; 39(3):331-341. PubMed ID: 29043922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Informing a collaborative-care model for delivering medication assisted treatment for opioid dependence (MATOD): An analysis of pharmacist, prescriber and patient perceptions.
    Cheetham A; Morgan K; Jackson J; Lord S; Nielsen S
    Res Social Adm Pharm; 2023 Mar; 19(3):526-534. PubMed ID: 36216753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.